More than 100 subcutaneous biologics have been approved and over 350 such drug candidates
Several approvedtherapeutic products, which are currently available as intravenous dosageforms, are being reformulated and evaluated for subcutaneous administration.Further, many existing drug delivery devices, including prefilled syringes, peninjectors, autoinjectors, needle-free injectors and large volume wearableinjectors, have been / are being designed for subcutaneous administration ofbiologics.
To order this 530+ page report, which features160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The USD 180+ billion (by 2030) financialopportunity associated with subcutaneous biologics, affiliated drug deliverysystems and subcutaneous formulation technology licensing deals, has beenanalyzed across the following segments:
§ Phase of development
§ Approved
§ Pre-registration& Phase III
§ Phase II & PhaseII/III
§ Type of molecule
§ Cell and genetherapies
§ Monoclonal antibodies
§ Proteins
§ Peptides(recombinant)
§ Vaccines
§ Others
§ Target therapeuticarea
§ Autoimmune disorders
§ Blood disorders
§ Bone disorders
§ Genetic disorders
§ Metabolic disorders
§ Neurologicaldisorders
§ Oncological disorders
§ Respiratory disorders
§ Others
§ Type of drug deliverysystem
§ Large volume wearableinjectors
§ Autoinjectors
§ Prefilled syringes
§ Needle-free injectors
§ Drug reconstitutionsystems
§ Revenues from licensingdeals
§ Upfront payments
§ Milestone payments
§ Key geographicalregions
§ North America
§ Europe
§ Asia Pacific
§ Rest of the World
TheSubcutaneous Biologics,Technologies and Drug Delivery Systems (3rdEdition), 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ Adocia
§ Ajinomoto Bio-PharmaServices
§ Arecor
§ Alteogen
§ Ascendis Pharma
§ AvadelPharmaceuticals
§ Camurus
§ Creative BioMart
§ Creative Biolabs
§ DURECT
§ Eagle Pharmaceuticals
§ Halozyme Therapeutics
§ MedinCell
§ Xeris Pharmaceuticals
§ Serina Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. SubcutaneousBiologics: Current Market Landscape
5. Case Study: LeadingSubcutaneous Biologics
6. SubcutaneousFormulation Technologies: Current Market Landscape
7. SubcutaneousFormulation Technology Developers: Company Competitiveness Analysis
8. SubcutaneousFormulation Technology Developers: Company Profiles
9. Partnerships and Collaborations
10. SubcutaneousDrug Delivery Systems: Current Market Landscape
11. SwotAnalysis
12. MarketForecast and Opportunity Analysis
13. ConcludingRemarks
14. ExecutiveInsights
15. Appendix1: Tabulated Data
16. Appendix2: List Of Companies And Organization
Topurchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
ContactDetails
GauravChaudhary
+1(415) 800 3415
+44(122) 391 1091
